Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel small molecule drugs to treat inflammatory bowel disease (IBD) based on a paradigm of resolving inflammation.
In contrast to existing IBD therapies that work by inhibiting key steps in the inflammatory process, Thetis agents offer a fundamentally new immuno-resolving approach to IBD treatment based on promoting tissue repair and healing without suppressing normal immune function. Our agents deliver endogenous bioactive lipids that play a critical role in regulating the inflammatory immune response. Thetis achieves this through a proprietary technology platform that unlocks the potent pharmacology of these lipids as new molecular entities.
Thetis has two candidates in preclinical development. TP-252 is a unique derivative of eicosapentaenoic acid, which has been shown in an independent Phase 2 trial to be effective in treating ulcerative colitis. TP-252 is targeted as adjunct therapy over first-line 5-ASA therapy before escalation to more side-effect prone immune-suppressants and biologics. TP-317 is a unique derivative of newly discovered class of bioactive lipids known as specialized pro-resolving mediators. TP-317 has the potential to be a non-immunosuppressive alternative or complement to biologics for treatment of IBD.